The scale of the problem justifies the effort. Sudden cardiac death is characterized by high incidence, low survival rates, and, crucially, it often presents as the very first manifestation of an underlying cardiovascular disease. Studies cited in the review, including a 2025 analysis in the Journal of the American Heart Association of sudden cardiac death mortality in the United States between 1999 and 2022, and a 2025 study in JACC: Clinical Electrophysiology showing that sudden cardiac death is frequently the first sign of cardiovascular disease, underline how little opportunity clinicians have to intervene before the fatal arrhythmia strikes. Out-of-hospital survival rates remain low, and risk stratification tools, including electrocardiographic markers and clinical scores, capture only part of the danger. That gap has pushed researchers toward the genome and, more recently, the epigenome, in search of signals that identify vulnerable hearts before they fail.

The genetic story begins with common variation. The review summarizes single nucleotide polymorphisms and insertion/deletion variants associated with sudden cardiac death, discovered through two complementary strategies: candidate-gene studies, which examine genes chosen for their known roles in cardiac function, and genome-wide association studies, which scan the entire genome without prior assumptions. A recurring theme is that risk variants cluster in genes involved in cardiovascular function, signal transduction, and cellular metabolism. Among the candidates highlighted are variants in NOS1AP, CASQ2 and GPD1L associated with sudden death risk in coronary artery disease; polymorphisms in angiotensin-converting enzyme-related pathways; a TGFBR2 polymorphism linked to cardiac arrest risk; common variation in fatty acid metabolic genes; and a missense variant in the neuregulin 1 gene that, remarkably, has been associated with both schizophrenia and sudden cardiac death, hinting at shared biology between neural and cardiac electrical systems.

Insertion/deletion polymorphisms form a second, technically distinct layer of variation. These variants, in which short stretches of DNA are present or absent, can alter gene dosage, disrupt regulatory sequences, or change protein structure. The review catalogues a series of such variants reported largely in Chinese populations, including indels in CTH, HSPA1B, the 3′ untranslated region of COL1A2, STIM1, COX10, NPC1, DSG2, LTBP4, the MIR155HG locus, the 3’UTR of STAT5A, and the alpha2-adrenergic receptor gene, the latter identified in Finnish cohorts as a genetic risk factor for sudden cardiac death. Several of these variants sit in regulatory regions rather than coding sequences, which means their functional impact likely operates through altered gene expression, a mechanism that connects naturally to the epigenetic half of the review.

Genome-wide association studies have added their own landmarks. A protective locus at GPC5 was identified in 2010; a susceptibility locus at chromosome 2q24.2 was mapped in individuals of European ancestry in 2011; and subsequent efforts, including a comprehensive 2018 evaluation of the genetic architecture of sudden cardiac arrest published in the European Heart Journal, have refined the picture. Yet the review is candid about a persistent problem: missing heritability. Known variants explain only a fraction of the familial clustering and population-level risk that epidemiologists observe, a challenge familiar across complex-disease genetics since the influential 2009 Nature paper by Manolio and colleagues. Rare variants, gene-gene interactions, gene-environment interactions, and epigenetic modifications are all candidate explanations for the unexplained portion, and the Moscow team argues that only large-scale, integrative, multi-ethnic studies combining genomic, epigenomic and clinical data with functional validation will close the gap.

That argument leads directly to epigenetics, the layer of molecular regulation that changes gene activity without altering the DNA sequence itself. The review focuses on three principal mechanisms: microRNAs, DNA methylation, and histone modifications. MicroRNAs are short non-coding RNAs that bind target messenger RNAs and suppress their translation or trigger their degradation. In the cardiovascular system they are pervasive regulators, controlling everything from cardiac conduction to fibrosis. The classic example, miR-1, regulates the arrhythmogenic potential of the heart by targeting the gap junction gene GJA1 and the potassium channel gene KCNJ2, directly linking microRNA levels to the electrical stability of the myocardium. Other microRNAs, including members of the miR-29, miR-133 and miR-30 families, modulate cardiac fibrosis and matrix remodeling, processes that create the structural substrate for lethal arrhythmias.

What makes microRNAs especially attractive for sudden cardiac death research is their measurability in body fluids. Tissue-based microRNAs recovered from post-mortem heart samples and circulating microRNAs detected in plasma both act as mechanistic regulators of the disease process and have emerged as exploratory biomarker candidates. Studies have reported that miR-1, miR-499 and miR-208 are sensitive markers for diagnosing sudden death due to early acute myocardial infarction; that miR-3113-5p, miR-223-3p, miR-133a-3p and miR-499a-5p can discriminate sudden cardiac death; and that plasma extracellular vesicle microRNA-208b-3p and microRNA-143-3p show promise as predictive biomarkers in acute coronary syndrome. Circulating microRNAs have even been examined in relation to sudden death risk in patients with coronary heart disease and to outcomes after cardiac arrest. The forensic dimension is equally striking: quantitative analysis of miR-1, miR-133a and miR-26a in heart tissue and whole blood has been proposed as a tool to help pathologists differentiate causes of death when autopsies are inconclusive.

The review, however, refuses to oversell these findings. It notes that inconsistent directions of association, methodological heterogeneity, and limited independent validation currently preclude the clinical application of microRNA biomarkers. Different studies measure different microRNA panels in different sample types with different normalization strategies, and few results have been replicated in independent cohorts. DNA methylation studies of sudden cardiac death are even scarcer, but they suggest potential roles for imprinted genes and oxidative stress pathways. One notable thread involves Prader-Willi syndrome, an imprinting disorder in which cardiac causes of death are overrepresented; recent work shows that deficiency of the necdin gene, lost in the syndrome, attenuates cardiac contractility, and that loss of Snord116 protects cardiomyocyte kinetics during ischemic stress, providing mechanistic links between imprinted loci and cardiac vulnerability. Differential methylation in the GSTT1 regulatory region has also been reported in sudden unexplained death, pointing toward detoxification and oxidative stress as methylation-sensitive pathways relevant to arrhythmic risk.

Histone modifications and chromatin remodeling represent the most underexplored but most promising frontier. Histone acetylation and deacetylation, mediated by histone acetyltransferases and histone deacetylases, reshape chromatin accessibility and thereby tune the expression of entire gene programs. Experimental work has shown that class I HDACs regulate angiotensin II-dependent cardiac fibrosis, that the stress-activated kinase MKK7 governs the epigenetics of cardiac repolarization and arrhythmia prevention, and that HDAC3 and HDAC5 influence cardiac conduction disease and mitochondrial function through their control of transcription factors such as Nkx2.5, MEF2 and PGC-1alpha. A 2025 experimental study even used the DNA damage marker gamma-H2AX to detect DNA damage in heart tissue from sudden cardiac death victims, suggesting that chromatin-level injury signatures may be readable in post-mortem material. These findings remain at the level of mechanism rather than validated clinical markers, but they sketch a plausible route by which environmental stressors, from ischemia to toxic exposures, become permanently inscribed in cardiac chromatin and translate into electrical instability.

The overall message of the review is one of cautious momentum. The genetic and epigenetic landscape of non-familial sudden cardiac death is no longer blank: common and rare variants, regulatory indels, circulating microRNAs, methylation patterns and chromatin modifiers all contribute pieces to the puzzle. But the pieces do not yet assemble into a predictive model that a cardiologist could apply at the bedside, and the authors are explicit that translating these molecular insights into clinical practice will require large-scale, integrative and multi-ethnic studies that combine genomic, epigenomic and clinical data with functional validation. Until then, the review serves as both a map of what is known and a checklist of what remains undone, and it makes a compelling case that the missing heritability of sudden cardiac death may be hiding, at least in part, not in the sequence of the genome but in the chemical marks written upon it.

Subject of Research: Genetic and epigenetic determinants of non-familial sudden cardiac death

Article Title: Genetic and epigenetic landscape of non-familial sudden cardiac death

Article References: Natalia, B., Natalia, M., Maxim, K., Olga, F., & Ivan, K. (2026). Genetic and epigenetic landscape of non-familial sudden cardiac death. Molecular Biology Reports, 53(1), Article 1630. https://doi.org/10.1007/s11033-026-12821-8

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12821-8

Keywords: sudden cardiac death, genetic variants, single nucleotide polymorphism, insertion-deletion polymorphism, genome-wide association study, epigenetics, microRNA, DNA methylation, histone modification, chromatin remodeling, missing heritability, cardiac arrhythmia

The research team, led by cardiologists at Bozhou People’s Hospital in Anhui Province, China, together with a colleague at the First Affiliated Hospital of the University of Science and Technology of China, evaluated ChatGPT Plus 5.5 thinking, Gemini 3.5 Flash, Microsoft Copilot smart, DeepSeek-V4-pro, Doubao, and Perplexity. Rather than inventing test questions in a conference room, the investigators built a standardized set of 56 sudden-cardiac-death-related public consultation questions from an unusually broad evidence base: Google Trends search data, online patient forums, public question-and-answer platforms, clinical guidelines, expert consensus statements, systematic reviews, and qualitative interviews with patients and family members. The topics spanned the full landscape of lay concern about sudden cardiac death, including symptom triage, emergency response, cardiopulmonary resuscitation and automated external defibrillator use, inherited cardiac risk, myocarditis-related worries, returning to exercise after illness, screening, and decision-making about implantable cardioverter-defibrillators.

Each of the 56 questions was submitted once to each of the six chatbots between May 10 and May 16, 2026, generating 336 individual model-response items for analysis. Five senior cardiology raters, blinded to which chatbot had produced which answer, then scored every response across a battery of validated instruments: a safety assessment, an accuracy assessment, an empathy scale, the DISCERN instrument for judging the quality of written health information, the EQIP instrument for ensuring the quality of patient education materials, the JAMA benchmark criteria, and the Global Quality Scale. Readability was calculated separately using six formula-based indices. Statistical comparisons between models used Cochran’s Q test and Friedman tests, with Kendall’s W reported as the effect size, and the agreement among raters was strikingly high, with a Fleiss’ kappa of 0.856 for the safety domain and intraclass correlation coefficients ranging from 0.801 to 0.887 for the other manually assessed metrics.

The headline finding on safety was genuinely reassuring at first glance. Safe responses predominated across all six models, suggesting that the current generation of publicly accessible chatbots has largely absorbed the basic guardrails of cardiac emergency communication. But the more consequential finding was that responses containing potential safety concerns appeared in every chatbot’s output during the study window. ChatGPT Plus 5.5 thinking and Perplexity showed the highest observed proportions of safe responses, while Doubao showed the lowest. Importantly, the qualitative severity analysis found that most flagged responses contained only a single potential safety concern, and the distribution of concerns was concentrated at the low and low-to-moderate severity levels, with higher-severity problems occurring less frequently. That pattern is consistent with a technology that has improved substantially but has not yet reached the reliability threshold that safety-critical health communication demands.

The qualitative analysis of flagged responses is arguably the most clinically valuable part of the study, because it names the specific failure patterns that clinicians and developers can act on. The reviewers repeatedly identified answers that delayed emergency activation for chest pain, syncope, or post-viral symptoms—the classic red-flag presentations of sudden cardiac death where immediate escalation to emergency medical services is the single most important instruction. They found instances of over-reassurance about prevention, implying that a person’s risk had been dismissed when individualized assessment was warranted. They documented fixed return-to-exercise timelines after infection or COVID-19, offered as blanket rules rather than guidance tailored to a patient’s cardiac evaluation. Some responses gave pulse-check instructions that could delay the start of CPR, a direct contradiction of resuscitation guidance that emphasizes rapid compressions. Others delivered oversimplified advice on screening, electrolyte disturbances, or implantable cardioverter-defibrillator decisions, flattening genuinely complex clinical judgments into deceptively simple answers.

Beyond safety, the study revealed sharp and statistically significant differences between models on nearly every quality dimension. Accuracy differed significantly across the six chatbots, with a Kendall’s W of 0.864 indicating strong rank concordance among raters; ChatGPT Plus 5.5 thinking, Gemini 3.5 Flash, Microsoft Copilot smart, DeepSeek-V4-pro, and Perplexity achieved similar median accuracy scores, while Doubao performed lower. Empathy also differed significantly, with a Kendall’s W of 0.531, and DeepSeek-V4-pro recorded the highest observed empathy score—a notable result, since empathetic framing is increasingly recognized as a determinant of whether anxious users actually follow health advice. Significant differences emerged for DISCERN, EQIP, JAMA benchmark, and Global Quality Scale scores as well, all at P < 0.001, confirming that the choice of chatbot materially changes the quality of the health information a member of the public receives.

DeepSeek-V4-pro emerged as the strongest overall performer on information quality within this dataset, achieving the highest DISCERN and EQIP scores and the most favorable readability profile, while Gemini 3.5 Flash showed comparable EQIP performance and Microsoft Copilot smart recorded the highest JAMA benchmark score. Yet two weaknesses were universal. Transparency remained limited across the board: chatbots rarely made clear where their information came from, how current it was, or how confident users should be in it, which matters enormously when a reader must decide whether to trust an answer about inherited cardiac risk. And every model produced responses with relatively high reading-grade requirements, meaning that the very populations most likely to need accessible cardiac health information—older adults, people with limited health literacy, non-native speakers—may struggle to extract the key safety messages from dense, jargon-laden text.

The authors are admirably explicit about the limits of their own findings. Each question was sampled only once during a single defined week in May 2026, and all prompts were submitted in English through public interfaces accessed from China. Generative models are stochastic and continuously updated, so the same question asked a month later might yield a different answer. The researchers therefore frame their results as a time-, language-, and access-specific snapshot rather than a stable ranking of the underlying models. This caveat is not a weakness of the study but a feature of honest evaluation methodology in a field where the tools change faster than the literature can assess them, and it underscores why one-off benchmark scores should never be treated as permanent verdicts on any AI system.

The practical implications are clear for three audiences at once. For members of the public, the message is that chatbots can be useful for general education about sudden cardiac death—understanding what an implantable defibrillator does, why myocarditis follows some viral infections, or what screening involves—but they must never substitute for calling emergency services or consulting a clinician when symptoms suggest a cardiac emergency. For clinicians and public health communicators, the study identifies the exact content areas where AI guidance most often goes astray: emergency escalation, CPR and AED instructions, return-to-exercise timing after infection, individualized risk interpretation, and screening decisions. For developers, the study’s recommendations read as a roadmap: prioritize evidence-linked content, build clear red-flag escalation into every relevant response, adopt plain-language communication, and submit systems to ongoing expert review rather than one-time validation.

What makes this study resonate beyond cardiology is its methodological template. By combining blinded expert scoring across validated instruments with a fine-grained qualitative analysis of safety failures, and by anchoring the question set in the genuine concerns of patients and families, the researchers have shown how AI health tools should be evaluated: not with a single accuracy number, but across the full multidimensional surface of safety, accuracy, empathy, quality, transparency, and readability. Sudden cardiac death is an unforgiving test case—outcomes are measured in minutes, and a subtly wrong answer about chest pain or pulse-checking can be fatal. On that test, the six chatbots earned a qualified pass: good enough to inform, not yet good enough to advise alone. As generative AI becomes a default first stop for health questions worldwide, studies like this one provide the evidence base that regulators, developers, and clinicians will need to decide where these tools belong in the chain of care—and where they must, without exception, hand the user straight to a human.

Subject of Research: Evaluation of generative AI chatbots for public health consultation on sudden cardiac death

Article Title: Multidimensional evaluation of generative AI chatbots for public consultation on sudden cardiac death: safety, accuracy, empathy, reliability, quality, and readability across six models

Article References: Chen, Y., Ma, H., Wang, H., Chen, D., Wang, H., & Jiang, R. (2026). Multidimensional evaluation of generative AI chatbots for public consultation on sudden cardiac death: safety, accuracy, empathy, reliability, quality, and readability across six models. BMC Public Health. https://doi.org/10.1186/s12889-026-29766-z

Image Credits: AI Generated

DOI: 10.1186/s12889-026-29766-z

Keywords: generative AI, chatbots, sudden cardiac death, public health, CPR, AED, patient safety, health communication, readability, empathy, large language models, BMC Public Health

The research team, led by Javier Sanmartin and Roberto Elosua of the University of Vic-Central University of Catalonia, followed PRISMA guidelines and prospectively registered their protocol in PROSPERO. They searched PubMed, Scopus, and Web of Science from database inception through September 2023, with an updated search extending to June 2025. From 5,963 initially identified articles, the investigators retained 115 original studies after removing duplicates and screening titles, abstracts, and full texts. Risk of bias was assessed with the Joanna Briggs Institute Critical Appraisal Tool for Cross-Sectional Studies, and pooled estimates were generated using random-effects models with the Freeman-Tukey double arcsine transformation for proportions.

The headline number is 4 percent. Using the International-Seattle criteria, which define T-wave inversion as a negative T-wave of at least 1 millimeter in two contiguous leads, the pooled prevalence among athletes older than 16 years was 4 percent, with a 95 percent confidence interval of 3 to 6 percent. That figure, however, masks enormous variability: individual studies reported prevalences ranging from 0 to 42 percent, and the between-study heterogeneity, quantified by the I-squared statistic, exceeded 80 percent in most meta-analyses. The authors caution that the pooled estimate should be interpreted with this heterogeneity firmly in mind.

Location on the electrocardiogram matters enormously. Inversions were most common in the anterior leads V2 through V4, at roughly 3 percent, while inferior leads showed about 1 percent and lateral leads essentially 0 percent. This anatomical gradient carries clinical weight because lateral T-wave inversion is the pattern most frequently linked to confirmed structural heart disease. In the studies that evaluated cardiomyopathies among athletes with T-wave inversion, the most commonly identified conditions were hypertrophic cardiomyopathy, arrhythmogenic ventricular cardiomyopathy, and dilated cardiomyopathy, and lateral-lead inversions were disproportionately represented among those diagnosed.

Ethnicity emerged as a major modifier of prevalence. Black athletes showed an overall T-wave inversion rate of 13 percent, compared with 3 percent in Caucasian athletes, a difference consistent with known genetic, endocrine, and hemodynamic factors, including greater myocardial wall thickness and left ventricular mass. Notably, recent work cited in the review found that geographical origin within Africa also matters, with repolarisation abnormalities significantly more common among West African and Middle African athletes than among those from East or North Africa. Sex differences were smaller but present: women showed a slightly higher overall prevalence than men, 7 percent versus 5 percent, driven by anterior and inferior leads.

Perhaps the most striking comparative finding is that T-wave inversion is roughly 49 percent more common in athletes than in non-athletes. Across 14 studies that included control populations, the pooled prevalence ratio was 1.49, with a confidence interval of 1.13 to 1.97. The effect was strongest in the inferior leads, where the ratio reached 1.70. This supports the idea that intense training itself, through ventricular remodeling and autonomic changes, produces repolarisation patterns that would be considered abnormal in a sedentary person but are often physiological in an athlete.

The mechanisms behind these training-related inversions are diverse. The authors describe ventricular remodeling effects, including a high papillary muscle to left ventricular mass ratio and lateral displacement of the cardiac apex, which can explain anterior inversions. Structural variants such as left ventricular false tendons have also been implicated. Enhanced vagal tone in trained athletes activates acetylcholine-controlled potassium channels, reducing the action potential gradient between the epicardium and endocardium and altering the repolarisation vector. Myocardial ischemia, by contrast, can invert the repolarisation gradient in a pathological direction, which is one reason the finding cannot simply be dismissed.

Age adds another layer of nuance. In athletes aged 16 or younger, a juvenile T-wave inversion pattern in leads V1 through V3 is considered a normal variant, reflecting right ventricular dominance in early adolescence, and it generally regresses after age 16. The meta-analysis found this juvenile pattern in about 6 percent of young athletes. Interestingly, meta-regression identified age as the only variable that partially explained the heterogeneity between studies, with older athletes showing higher prevalence, a relationship the authors attribute to cumulative lifetime training volume.

On the critical prognostic question, the picture is murkier. Among 34 studies that assessed structural cardiomyopathies in athletes with T-wave inversion, most reported disease prevalence below 1 percent, though nine studies found rates between 1 and 10 percent and six exceeded 10 percent, likely reflecting deeper inversions, lateral predominance, referral-center recruitment, and more sensitive imaging such as cardiac magnetic resonance. Follow-up data were similarly heterogeneous: annual incidence rates of newly diagnosed cardiomyopathy ranged from 0 to 54.9 cases per 1,000 athletes, and major cardiovascular events ranged from 0 to 83.33 per 1,000 athlete-years. The authors attribute this wide spread to small samples, short follow-up, and selection biases, leaving the true event risk statistically uncertain.

The clinical message is a careful balance. T-wave inversion in athletes is more common than in the general population, most often involves the anterior leads, and frequently reflects benign exercise-induced remodeling, particularly in Black athletes and in younger age groups. Yet because it can also herald hypertrophic, arrhythmogenic, or dilated cardiomyopathy, especially when it appears in lateral leads or is accompanied by ST-segment depression, a thorough evaluation remains essential. The authors call for international, standardized, prospective studies with adequate sample sizes, uniform diagnostic protocols incorporating echocardiography, exercise testing, Holter monitoring, and cardiac magnetic resonance, and long-term follow-up to finally pin down which athletes with inverted T-waves truly need to worry.

Subject of Research: Prevalence and prognostic significance of T-wave inversions on electrocardiograms in athletes

Article Title: Frequency and Prognostic Significance of T-wave Inversions in Athletes: A Systematic Review and Meta-analysis

Article References: Sanmartin, J., Cartanya-Bonvehi, J., Valenzuela, H., Carballeira, L., Montserrat, S., Baranchuk, A., & Elosua, R. (2026). Frequency and Prognostic Significance of T-wave Inversions in Athletes: A Systematic Review and Meta-analysis. Sports Medicine – Open, 12(1), Article 147. https://doi.org/10.1186/s40798-026-01115-9

Image Credits: AI Generated

DOI: 10.1186/s40798-026-01115-9

Keywords: T-wave inversion, athletes, electrocardiogram, sudden cardiac death, cardiomyopathy, sports cardiology, meta-analysis, athlete's heart, ECG screening, ventricular remodeling, hypertrophic cardiomyopathy, prevalence

The clinical stakes are considerable. Cardiovascular diseases claimed roughly 19.8 million lives in 2022, about 32 percent of all global deaths, and arrhythmias sit at the dangerous intersection of stroke, heart failure, and sudden cardiac death. Electrophysiologists routinely rely on electroanatomical voltage mapping to find the scarred or electrically remodeled tissue that harbors these rhythms. The technique works by measuring peak-to-peak electrogram amplitudes across the heart and flagging regions that fall below established cut-off values as abnormal. But those cut-off values are anything but universal. They differ between the atria and the ventricles, between unipolar and bipolar recording configurations, between mapping technologies, and—critically for the research community—between species. Thresholds have been published for human, swine, ovine, canine, and rat hearts, yet despite decades of rabbit-based electrophysiology research, no standardized epicardial voltage values existed for the rabbit model. That gap is what the Brazilian team set out to close.

The experimental platform is a tour de force of controlled preparation. Nine New Zealand White rabbit hearts were extracted, heparinized, and connected to a Langendorff perfusion system, which pushes oxygenated, warmed Krebs–Henseleit solution backward through the aorta at a constant pressure of 70 to 80 millimeters of mercury, keeping the tissue alive and physiologically stable outside the body. Custom multi-electrode arrays—16 platinum electrodes arranged in a four-by-four grid on flexible PET substrates—were placed directly on the epicardium of the right atrium, the left atrium, and the anterior ventricular surface. The atrial arrays used 2-millimeter electrode spacing; the ventricular array spread its electrodes 4 millimeters apart to cover more tissue. Signals were acquired in a unipolar configuration at 4 kilohertz using Intan amplifiers and an Open Ephys acquisition board, all referenced to a tinned copper ring fixed around the aorta. To eliminate the motion artifacts that plague contracting hearts, the team perfused the muscle-relaxant blebbistatin, a selective myosin II inhibitor that uncouples contraction from electrical activity without dampening the electrical signals themselves.

With the hearts beating electrically but not mechanically, the researchers recorded baseline sinus rhythm from all three chambers—roughly 1,600 unipolar and 1,000 bipolar peak-to-peak amplitudes per chamber—after careful preprocessing that included detrending, 60-hertz notch filtering, and zero-phase Butterworth bandpass filtering between 0.5 and 250 hertz. Bipolar signals were derived by subtracting adjacent electrode pairs in horizontal, vertical, and diagonal orientations, with the best-defined morphology selected to ensure the derivation aligned with the local wavefront direction. The healthy-tissue threshold was then defined using the 95th percentile of the amplitude distribution, a non-parametric criterion widely used in clinical electroanatomical mapping that avoids assumptions of normality and resists distortion by extreme values. The resulting numbers are strikingly chamber-specific: unipolar thresholds came out at 7.4 millivolts for the right atrium, 8.9 millivolts for the left atrium, and 17.4 millivolts for the ventricle, while the corresponding bipolar thresholds were 4.1, 5.7, and 9.5 millivolts. Ventricular electrograms dwarfed atrial ones, a reflection of the ventricles’ greater muscle mass, more synchronized wavefronts, and different tissue architecture, and unipolar amplitudes systematically exceeded bipolar ones because unipolar electrodes sense a broader territory while bipolar measurements capture only the local voltage gradient.

Having established the baseline, the team turned to the heart of the question: what happens to these voltages when arrhythmia strikes? Using carbachol to modulate autonomic tone and pinacidil, an ATP-sensitive potassium channel opener, to shorten action potential duration, the researchers primed the hearts for arrhythmia and then induced atrial tachycardia, ventricular tachycardia, and ventricular fibrillation through burst pacing protocols delivered at 20 to 50 hertz. The amplitude collapses they documented were dramatic and rhythm-dependent. In one heart, ventricular peak-to-peak amplitudes fell from 31.0 millivolts during sinus rhythm to 8.3 millivolts during ventricular tachycardia, with a rank-biserial correlation of 1.000—the maximum possible effect size—and a median paired difference of 21.68 millivolts. During ventricular fibrillation, amplitudes crashed from 23.6 to 4.8 millivolts, again with an almost maximal effect size of 0.997. Cycle lengths shortened in parallel, from 278.7 to 184.4 milliseconds in tachycardia and from 460.2 to 145.6 milliseconds in fibrillation, consistent with the escalating frequency and disorganization of activation.

The atrial story proved more nuanced. During induced atrial tachycardia, the right atrium showed only a modest amplitude reduction, from 18.2 to 16.1 millivolts, with a moderate effect size of 0.348. The left atrium, by contrast, suffered a far steeper decline, from 28.2 to 9.9 millivolts, with an almost maximal effect size of 0.997 and a median paired difference of 15.94 millivolts. This chamber-specific asymmetry suggests that the left atrium is substantially more susceptible to amplitude suppression during rapid activation, a finding that resonates with clinical observations that the left atrium often dominates the substrate of atrial fibrillation. The researchers attribute the amplitude losses to impaired spatial coherence of electrical activity: as activation rates climb, wavefronts fragment, opposing vectors cancel one another, and the coordinated myocardial activation that produces large, clean electrograms disintegrates.

Perhaps the most visually compelling results came from the longitudinal voltage maps themselves. Because the arrays stayed fixed on the epicardium throughout each experiment, the team could compare maps of the identical tissue patch across four sequential states: baseline sinus rhythm, sinus rhythm immediately before the arrhythmia, the arrhythmia itself, and sinus rhythm after the arrhythmia terminated. During atrial tachycardia, this revealed a fascinating split personality. Certain electrodes—numbers 3, 4, and 15 on the right atrial array—showed low voltage persistently across every sinus rhythm map and during the arrhythmia, marking them as rhythm-independent, structurally suspect regions. But a second cluster of electrodes—1, 5, 9, 13, and 14—dropped below threshold only during the tachycardia and recovered fully once sinus rhythm returned. Low-voltage area coverage on that array jumped from zero percent at baseline to 18.75 percent before the arrhythmia, 50 percent during it, and back to 18.75 percent afterward. Those transient zones, the researchers concluded, represent a functional substrate: rate-dependent electrophysiological behavior that appears and disappears with the rhythm rather than fixed tissue damage.

The ventricular fibrillation maps told a fundamentally different story. What began as a homogeneous ventricular map—every electrode comfortably above the 17.4-millivolt healthy threshold—collapsed into near-universal low voltage once fibrillation began, with global amplitudes falling to 0.7 millivolts and every electrode dropping below 4 millivolts. Crucially, the suppression did not resolve when sinus rhythm returned. Post-arrhythmia maps showed only partial recovery, with all electrodes still below threshold and the same electrodes that had been most severely suppressed—89, 93, and 94—remaining under 2 millivolts. The spatial persistence of these low-voltage patterns across every time point after their first appearance suggests a substrate behavior compatible with sustained disruption of ventricular electrical organization, a pattern the authors interpret as predominantly structural in character, though they are careful to note that histological validation would be needed to confirm true tissue remodeling.

The authors are candid about the limitations that frame these conclusions. The three arrhythmias studied involve distinct mechanisms in different chambers, so their voltage patterns cannot be directly compared as evidence of a common arrhythmogenic pathway. The arrhythmia recordings were obtained in the continuous presence of blebbistatin, carbachol, and pinacidil, any of which could influence conduction, repolarization, and electrogram amplitudes. And the thresholds themselves are specific to the custom electrode geometry, spacing, signal-processing pipeline, and ex vivo preparation used here—they are platform-specific reference values, not universal biological boundaries, and would need validation before extrapolation to other rabbit mapping systems or in vivo settings. Within those bounds, however, the study delivers something the field has lacked: a quantitative, chamber-specific framework for interpreting voltage maps in the most widely used small-animal model of cardiac electrophysiology.

The broader implication is that voltage mapping, long treated as a static snapshot of scar and fibrosis, is actually a window into a living, breathing electrical landscape. The degree of amplitude suppression tracks the degree of electrophysiological organization, rising progressively from atrial tachycardia through ventricular tachycardia to fibrillation, and the spatial behavior of low-voltage regions distinguishes functional, rhythm-dependent abnormalities from persistent, potentially structural ones. For researchers using the isolated rabbit heart to probe conduction heterogeneity, electrophysiological remodeling, and the mechanisms that initiate and sustain lethal rhythms, the new reference values and the longitudinal mapping approach provide both a calibration standard and a methodological template. The next step, the authors suggest, is to pair these electrical maps with complementary structural validation, so that the flickering low-voltage zones captured on the epicardial surface can be traced to their ultimate biological causes—and, perhaps one day, to better-targeted therapies in human patients.

Subject of Research: Epicardial voltage mapping of arrhythmogenic substrate dynamics in Langendorff-perfused isolated rabbit hearts

Article Title: Peak-to-Peak Voltage Mapping Reveals Dynamic Arrhythmogenic Substrate Behavior in Isolated Rabbit Hearts

Article References: Peak-to-Peak Voltage Mapping Reveals Dynamic Arrhythmogenic Substrate Behavior in Isolated Rabbit Hearts. (n.d.). https://doi.org/10.1007/s10439-026-04382-5

Image Credits: AI Generated

DOI: 10.1007/s10439-026-04382-5

Keywords: cardiac electrophysiology, voltage mapping, arrhythmogenic substrate, rabbit heart model, Langendorff perfusion, atrial tachycardia, ventricular tachycardia, ventricular fibrillation, electrograms, low-voltage areas, multi-electrode arrays, sudden cardiac death

The central problem the researchers set out to solve is one of incomplete explanation. Pathogenic or likely pathogenic variants in sarcomere-encoding genes, the category the team abbreviates as SARC-HCM-P/LP, account for only about one-third of hypertrophic cardiomyopathy cases. The remaining majority of patients have no detectable single-gene culprit, and even among confirmed carriers, the condition displays notoriously variable penetrance: some people harboring a dangerous variant develop severe disease early in life, while others reach old age with hearts that function normally. This uneven expressivity has long hinted that something beyond the rare variant itself, most plausibly the cumulative influence of thousands of common genetic variants scattered across the genome, helps determine who actually becomes ill and how sick they become.

Earlier attempts to capture that polygenic contribution ran into a stubborn equity problem. Existing polygenic risk scores for hypertrophic cardiomyopathy were built almost exclusively from genome-wide association studies of European-ancestry populations, and when applied to individuals of African, East Asian, Hispanic, or other ancestries, their predictive performance deteriorated sharply. This limitation mirrors a broader and well-documented weakness of genomics: because most large genetic datasets over-represent people of European descent, risk scores trained on them often fail the very populations that already bear disproportionate burdens of cardiovascular disease and face greater barriers to genetic diagnosis. The new study was designed from the ground up to confront that disparity rather than treat it as an afterthought.

To construct the score, the team drew on genome-wide association summary statistics from three complementary sources: the BioBank Japan, the Million Veteran Program, and a meta-analysis of seven European-ancestry cohorts. By combining association signals from Japanese, multiethnic American, and European datasets, the investigators built a score intended to capture disease-relevant variants across the genetic ancestry continuum rather than within a single population. The statistical machinery behind such scores involves weighting millions of single nucleotide polymorphisms according to their measured association with disease risk, then summing those weighted contributions for each individual to yield a single number representing inherited polygenic susceptibility. Methods of this kind, including Bayesian shrinkage approaches refined in recent years, allow researchers to distill a usable clinical signal from noisy, genome-scale data while guarding against overfitting.

The validation stage took place in a genuinely diverse national cohort: participants in the United States-based All of Us Research Program, one of the largest and most ancestrally diverse biomedical datasets ever assembled. The results were unambiguous. Individuals whose polygenic score placed them in the top quintile of the population had a 2.11-fold increased risk of developing hypertrophic cardiomyopathy compared with the rest of the population. That effect size, for a common-variant composite score alone, is clinically meaningful and rivals the discriminatory power that polygenic scores have achieved for more common conditions such as coronary artery disease. The score also improved overall risk stratification and showed trends toward improved ancestry-specific prediction, suggesting that the multiancestry training strategy partially, if not perfectly, mitigated the performance cliff that plagues European-derived scores.

The most striking finding, however, emerged when the researchers layered the polygenic score on top of the rare-variant picture. Among carriers of pathogenic or likely pathogenic sarcomere variants, individuals in the highest polygenic score quintile faced nearly a seventy-fold higher risk of actually developing hypertrophic cardiomyopathy compared with low-scoring counterparts. This is precisely the kind of result that cardiologists and genetic counselors have been waiting for. Variable penetrance among variant carriers has made counseling agonizingly uncertain: telling a young person they carry a disease-causing mutation without being able to say whether that mutation will ever manifest is of limited clinical use. A polygenic measure that helps distinguish the carriers likely to develop disease from those likely to remain unaffected converts a static genetic diagnosis into a dynamically graded risk estimate.

Beyond prediction of who develops disease, the score carried prognostic weight. Among individuals already diagnosed with hypertrophic cardiomyopathy, a higher polygenic score was associated with adverse cardiovascular outcomes, indicating that the same aggregate burden of common variants that raises disease susceptibility also shapes disease severity and trajectory. This suggests that polygenic information could eventually inform not only screening decisions but also surveillance intensity and management priorities for diagnosed patients. Extended analyses reinforced the pattern: among carriers of predicted deleterious variants, disease prevalence rose steadily across polygenic score quintiles, with the highest quintile showing roughly 2.4-fold higher penetrance than the lowest, and hazard ratios climbing in a graded fashion as score category increased.

The technical infrastructure supporting the study reflects the maturing standards of the polygenic risk score field. The investigators performed careful quality control, addressed the statistical pitfall known as Winner’s Curse that inflates effect estimates in discovery samples, and evaluated performance using measures including odds ratios per standard deviation of score change and area under the receiver operating characteristic curve across ancestry groups. In a notable commitment to transparency and reproducibility, the team made its analysis code publicly available on GitHub and deposited the underlying genome-wide association summary statistics in the GWAS Catalog, enabling other researchers to replicate, extend, or adapt the score for their own populations. Individual-level participant data remain accessible through the All of Us Researcher Workbench under its data use agreements.

The clinical implications reach well beyond hypertrophic cardiomopathy itself. Hypertrophic cardiomyopathy affects roughly one in several hundred people and remains a leading cause of sudden cardiac death in young athletes, yet many cases go undiagnosed until a catastrophic event occurs. A validated, ancestry-fair risk score could be deployed to flag individuals who warrant echocardiographic screening, genetic testing, or closer longitudinal follow-up, potentially catching disease before it strikes. For gene-positive family members of affected patients, combining sarcomere variant status with a polygenic score could personalize the schedule of cardiac imaging and the timing of preventive interventions, including the newer generation of cardiac myosin inhibitors that have transformed pharmacologic management of the disease.

The authors and observers of the field alike caution that scores of this kind are not yet ready to replace clinical judgment or guideline-based testing. The ancestry-specific performance gains, while encouraging, remained trends rather than definitive demonstrations, and further validation in independent, prospective cohorts will be essential before polygenic information enters routine cardiology practice. Questions about how best to communicate a seventy-fold relative risk to a worried variant carrier, and how insurers and employers might use such information, also demand careful attention. Still, the study marks a turning point: it demonstrates that the variable penetrance puzzle of hypertrophic cardiomyopathy is, at least in part, quantitatively solvable, and that the solution can be built to serve populations of all ancestries rather than a genetically privileged few. As multiancestry genomic resources continue to grow, the integration of rare variant status and polygenic background promises to become a standard pillar of precision cardiovascular medicine, reshaping how inherited heart disease is predicted, counseled, and ultimately prevented.

Subject of Research: Development and validation of a multiancestry polygenic risk score for hypertrophic cardiomyopathy risk stratification

Article Title: A multiancestry polygenic risk score improves stratification in patients with hypertrophic cardiomyopathy

Article References: Bal, H. S., Pampana, A., Nayak, A., Gaonkar, M., Patel, S., Yerabolu, K., Vekariya, N., Patel, N., Kalra, R., Li, P., Arora, G., & Arora, P. (2026). A multiancestry polygenic risk score improves stratification in patients with hypertrophic cardiomyopathy. Nature Cardiovascular Research, 5(9), 891-903. https://doi.org/10.1038/s44161-026-00866-8

Image Credits: AI Generated

DOI: 10.1038/s44161-026-00866-8

Keywords: hypertrophic cardiomyopathy, polygenic risk score, multi-ancestry genomics, sarcomere variants, variable penetrance, All of Us Research Program, cardiovascular genetics, risk stratification, precision medicine, genome-wide association study, genetic counseling, sudden cardiac death

The study, registered in PROSPERO (CRD420251082728) and conducted according to PRISMA guidelines, tackled a problem that has long plagued the field: the wildly varying estimates of diagnostic yield reported across individual molecular autopsy studies, which have ranged from single digits in early candidate-gene screens to more than 30 percent in some whole-exome sequencing cohorts. The authors recognized that much of this variability was an artifact of inconsistent variant classification. Older studies frequently counted variants of uncertain significance, or VUS, as positive findings, inflating apparent yields, while others applied gene-disease validity standards that would not survive contemporary scrutiny. By correcting all reported yields to ACMG-compatible classification, in which only pathogenic and likely pathogenic variants in genes with established disease associations count as diagnostic, the researchers produced a standardized figure that clinicians and forensic investigators can actually use when deciding whether to invest in postmortem genetic testing.

Beyond the headline yield, the meta-analysis revealed a clear relationship between sequencing strategy and diagnostic success. Broader sequencing approaches, such as whole-exome and large multi-gene panels, showed modestly but significantly higher yields than restricted candidate-gene panels, with an odds ratio of 1.36 (95% confidence interval 1.09–1.70; p = 0.006). This finding confirms quantitatively what many in the field have suspected: casting a wider genomic net catches more causative variants. But the wider net comes at a cost. Broader sequencing also generated a substantially greater burden of VUS, variants whose clinical significance cannot be determined from available evidence. These uncertain findings pose a genuine dilemma in the postmortem setting, where the deceased cannot be examined clinically and phenotype information is limited to circumstantial accounts of the death itself.

The analysis also stratified results by age, uncovering a striking pattern. Young adult and adult cohorts showed the highest pooled diagnostic yields, consistent with the notion that in these age groups, deaths are more likely to be driven by single, highly penetrant variants in well-characterized arrhythmia and cardiomyopathy genes. In contrast, infant and pediatric cohorts displayed a broader multisystem genomic architecture, implicating genes involved in diverse developmental and metabolic pathways rather than a narrow set of cardiac ion channel genes. These younger cohorts also carried higher VUS burdens, reflecting both the wider genetic landscape involved in early-life sudden death and the relative paucity of validated disease genes for many pediatric conditions. This has practical implications: laboratories interpreting molecular autopsy results in infants and children should expect more ambiguous findings and may need to consider syndromic and multisystem diagnoses that would not arise in adult cases.

Across all cohorts, a recurring cast of culprit genes emerged. RYR2, which encodes the cardiac ryanodine receptor governing calcium release from the sarcoplasmic reticulum, was among the most frequently implicated, consistent with its central role in catecholaminergic polymorphic ventricular tachycardia, a condition that causes sudden death during exertion or emotional stress in structurally normal hearts. SCN5A, encoding the cardiac sodium channel responsible for the rapid upstroke of the cardiac action potential, appeared repeatedly, as did KCNQ1 and KCNH2, the potassium channel genes underlying the most common forms of long QT syndrome. Structural heart genes also featured prominently: TTN, encoding the giant sarcomeric protein titin, and MYBPC3, encoding myosin-binding protein C, both well-established causes of inherited cardiomyopathy. Together, these genes represent the biological backbone of unexplained sudden death, spanning the electrical and mechanical machinery of the heart.

Perhaps the most clinically consequential finding of the review concerns what happens after a positive molecular autopsy result. Thirty-five of the included studies provided family-translation data, documenting what occurred when genetic findings were communicated back to surviving relatives. The results paint a compelling picture of molecular autopsy as not merely a diagnostic tool for the deceased, but as the entry point into a cascade of preventive medicine for the living. Genotype-positive relatives, meaning family members who carry the same variant identified in the decedent, were frequently identified through cascade screening, as were phenotype-positive relatives who showed clinical evidence of disease on cardiac evaluation even without the family variant. Formal segregation analysis, in which the variant’s co-transmission with disease is tracked through a pedigree, was commonly performed to strengthen or refute pathogenicity assignments. Critically, clinically actionable interventions were frequently reported: beta-blockers, implantable cardioverter-defibrillators, lifestyle modifications, and targeted pharmacotherapy that can prevent the same sudden death from claiming another member of the family.

The concept of “family translation” is central to the authors’ argument about the true value of molecular autopsy. A 13 percent yield might seem underwhelming if viewed purely as a diagnostic statistic for individual deaths. But when reframed as a population-level intervention, the calculus changes dramatically. Each diagnostic result in a decedent potentially triggers the identification of multiple at-risk relatives, many of whom are asymptomatic but carry a life-threatening, treatable condition. In inherited arrhythmia syndromes such as long QT syndrome, preventive treatment can reduce sudden death risk dramatically, meaning that a single molecular autopsy result may avert multiple premature deaths across a family tree. The authors argue that contemporary ACMG-compatible molecular autopsy should be understood not as a forensic curiosity but as a cornerstone of family-based preventive genomic medicine.

The technical rigor of the review also sheds light on the maturation of the field itself. Early molecular autopsy efforts in the late 1990s and 2000s relied on Sanger sequencing of a handful of candidate genes, most famously the three major long QT syndrome genes, producing yields that reflected the narrowness of the query rather than the full genetic substrate of sudden death. The advent of next-generation sequencing enabled panels of dozens to hundreds of genes, and subsequently whole-exome and whole-genome approaches that could interrogate the entire coding sequence. Each technological generation brought higher raw yields but also greater complexity in interpretation, as the number of rare variants of unknown significance grew in parallel with the number of genes examined. The ACMG framework, with its five-tier classification system from benign to pathogenic and its emphasis on gene-disease validity, emerged as the necessary corrective to this interpretive chaos. The new meta-analysis demonstrates that applying this framework uniformly across the published literature produces a diagnostic yield estimate that is far more trustworthy than the scattered figures that preceded it.

The findings carry immediate implications for forensic practice and health policy. In many jurisdictions, molecular autopsy is not routinely performed or is not covered by public health systems, and medical examiners often lack access to genetic counseling services needed to translate results to families. The demonstration that broad sequencing outperforms restricted panels, even after accounting for the VUS burden, argues for investment in comprehensive postmortem genomic testing rather than piecemeal candidate-gene approaches. At the same time, the persistent VUS problem underscores the need for ongoing variant reclassification efforts, as variants once deemed uncertain may be reclassified as knowledge accumulates, converting non-diagnostic results into actionable findings years after the original test. The authors also highlight the importance of structured pathways connecting forensic genetics laboratories with clinical cardiology and genetics services, so that a positive postmortem finding reliably triggers cascade screening rather than languishing in a forensic report.

The review is not without limitations inherent to its design. The substantial heterogeneity observed across studies, acknowledged by the authors, reflects genuine differences in cohort composition, sequencing technology, reporting standards, and geographical ancestry of the populations studied. Publication bias likely inflates yield estimates, as studies finding nothing reportable are less likely to be published. And because the analysis relies on previously published data, the quality of family-translation reporting varied considerably, making it difficult to quantify precisely how often molecular autopsy results lead to clinically meaningful interventions in relatives. Nonetheless, by standardizing variant classification across 4,041 cases, the study provides the most reliable benchmark yet available for what families and clinicians can realistically expect from postmortem genetic testing.

As molecular autopsy moves from an emerging experimental tool to an established component of sudden death investigation, this meta-analysis arrives at a pivotal moment. Its central message is nuanced but clear: molecular autopsy delivers a modest yield when measured against modern classification standards, but its true power lies in what happens downstream. For the roughly one in eight families who receive a genetic explanation, the result converts an inexplicable tragedy into actionable medical knowledge. For the field as a whole, the study establishes a rigorous, ACMG-corrected baseline against which future improvements in sequencing technology, variant interpretation, and family-centered care can be measured.

Intussusception, a phenomenon classically associated with the gastrointestinal tract, involves the telescoping of one segment of a hollow organ into an adjacent part, commonly invoking acute obstruction and ischemia. Its occurrence within a coronary artery vessel had been hitherto undocumented in human clinical cases, making this report a pioneering revelation. The coronary arteries, responsible for perfusing the myocardium, are critical conduits whose structural integrity is paramount for sustaining life. The unusual inward folding or invagination of a coronary artery segment in this instance led to catastrophic hemodynamic occlusion.

The clinical manifestation culminating in this fatal event was sudden cardiac death (SCD)—a tragic endpoint defined by an abrupt loss of cardiac function leading to death, often within minutes of symptom onset. SCD accounts for a significant proportion of mortality worldwide, predominantly linked to arrhythmias, myocardial infarction, or structural heart defects. However, the underlying causes can be cryptic in numerous cases, emphasizing the value of detailed post-mortem investigations such as this one.

The forensic autopsy unveiled intussusception as the causal lesion by demonstrating the unique morphological alterations within a coronary artery. The segment of the intussuscepted vessel created a mechanical obstruction akin to a physiological trap, severely restricting blood flow to critical myocardial territories. Microscopic examination reinforced the diagnosis by revealing disruption of the intimal layers and vascular wall architecture, hinting at the complex pathophysiological cascade that ensued prior to death.

What renders this case especially compelling is the rarity and diagnostic elusiveness of coronary artery intussusception. Unlike more familiar coronary pathologies such as atherosclerotic plaque rupture or embolism, intussusception lacks hallmark clinical signs and is invisible to conventional imaging techniques employed ante-mortem. The absence of warning symptoms, coupled with sudden occlusion, underscores this entity as a stealthy perpetrator in sudden cardiac fatalities.

The etiology behind the spontaneous intussusception remains speculative but intriguing hypotheses propose localized vessel wall weakness or aberrant contractile forces as contributing factors. Autoimmune or inflammatory processes could render the vascular layers susceptible to delamination, paving the way for telescoping under normal hemodynamic stress. Alternatively, congenital structural variants might predispose individuals to such vascular vulnerabilities.

Understanding these mechanisms not only expands the scientific comprehension of coronary artery diseases but also beckons a paradigm shift in how unexplained sudden cardiac deaths are approached. It challenges forensic pathologists and clinicians to consider uncommon vascular anomalies during autopsy and clinical evaluation, potentially refining protocols and preventative strategies.

The implications span beyond academic fascination; recognizing coronary intussusception can influence medico-legal outcomes and guide family counseling concerning inheritable risks. Genetic investigations alongside detailed histopathological scrutiny could pave the way for identifying at-risk individuals through innovative biomarkers or imaging modalities yet to be developed.

This case report also prompts a reexamination of current cardiovascular imaging technologies. Conventional angiography or computed tomography may not capture subtle intramural vascular distortions characteristic of intussusception. Future advancements like high-resolution intravascular ultrasound or optical coherence tomography might prove indispensable in detecting such elusive vascular phenomena.

Critically, this discovery sparks curiosity regarding potential therapeutic interventions. If identified preemptively, surgical correction or endovascular approaches might prevent catastrophic myocardial ischemia. However, the rarity and unpredictable nature of intussusception pose formidable challenges to the formulation of clinical guidelines.

From an investigative standpoint, the interdisciplinary collaboration between forensic medicine and cardiology was pivotal in unraveling this case. Such synergy exemplifies the importance of diverse expertise converging to decode perplexing medical mysteries, enhancing the collective arsenal against sudden cardiac deaths.

The broader medical community stands to gain immensely from heightened awareness of coronary artery intussusception. Educating clinicians, pathologists, and radiologists about this rare entity could incite more meticulous evaluations and reporting of similar cases globally. A growing database can yield epidemiological insights and inform future research trajectories.

Ultimately, this seminal case report is a clarion call to deepen investigative resolve in cases of sudden cardiac death where common etiologies fall short. It epitomizes the ceaseless quest for knowledge in medicine—unveiling hidden pathologies that lurk beneath the surface, forever reshaping our understanding of human health and disease.

Subject of Research: Sudden cardiac death caused by coronary artery intussusception

Article Title: Sudden cardiac death due to intussusception of a coronary artery: a case report

Article References:
Attico, F., Di Paola, F., De Nadai, M. et al. Sudden cardiac death due to intussusception of a coronary artery: a case report. Int J Legal Med (2025). https://doi.org/10.1007/s00414-025-03632-w

Image Credits: AI Generated